Annual report pursuant to Section 13 and 15(d)

Acquisitions - Narrative (Details)

v3.23.2
Acquisitions - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Jul. 01, 2022
Apr. 06, 2021
Apr. 02, 2021
Oct. 20, 2020
Jun. 30, 2023
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Cash paid, net of cash acquired           $ 101,184   $ 225,352
Goodwill, Purchase Accounting Adjustments             $ 4,407  
Namocell Inc                
Maximum contingent consideration $ 25,000       $ 25,000 25,000    
Cash paid, net of cash acquired $ 101,184       101,184      
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual           6,400    
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual           9,300    
Namocell Inc | Developed technology                
Finite-Lived Intangible Asset, Useful Life (Year)       13 years        
Namocell Inc | Customer relationships                
Finite-Lived Intangible Asset, Useful Life (Year)       10 years        
Eminence Biotechnology                
Business Acquisition, Percentage of Voting Interests Acquired       47.60%        
Fair value of noncontrolling interest in Eminence       $ 9,000        
Payments to Acquire Businesses, Gross     $ 6,000          
Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total     57.40%          
Cash paid, net of cash acquired       $ 9,800       9,765
Asuragen, Inc.                
Maximum contingent consideration   $ 105,000     $ 105,000 $ 105,000    
Adjustments to deferred taxes and goodwill             $ 4,400  
Cash paid, net of cash acquired   $ 216,000           $ 215,587
Asuragen, Inc. | Developed technology                
Finite-Lived Intangible Asset, Useful Life (Year)   14 years     13 years 13 years    
Asuragen, Inc. | Customer relationships                
Finite-Lived Intangible Asset, Useful Life (Year)   16 years     4 years 4 years    
Asuragen, Inc. | Trade names                
Finite-Lived Intangible Asset, Useful Life (Year)   5 years            
Asuragen, Inc. | Non-competition agreement                
Finite-Lived Intangible Asset, Useful Life (Year)   3 years            
Asuragen, Inc. | Trade names and non-competition agreement                
Finite-Lived Intangible Asset, Useful Life (Year)         3 years 3 years